双作用芳酶/COX-2的治疗潜力的最新进展
Ali Aliabadi1, Mobina Tajdari1,2, Sara Fakharinia1
1Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Anti-cancer agents in medicinal chemistry
|March 28, 2025
概括
新型芳香酶抑制剂对于对抗耐药性乳腺癌至关重要. 本综述探讨了新的双重作用分子,旨在克服耐药性并提高抗癌治疗疗效.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 芳酶 (CYP19A1) 将雄激素转化为雌激素,从而促进激素依赖的乳腺癌.
- 瘤细胞产生的雌激素有助于内分泌治疗耐药性.
- 目前的芳酶抑制剂面临越来越多的耐药性,需要新的治疗策略.
研究的目的:
- 审查新开发的具有潜在抗癌作用的芳酶抑制剂.
- 突出新型抑制剂在克服内分泌抵抗方面的重要性.
- 探索双抑制分子以提高抗癌疗效.
主要方法:
- 关于芳香酶抑制剂的最新科学文献的综述.
- 对新型分子设计的分析,包括双重作用化合物.
- 评估克服药物耐药性的潜在机制.
主要成果:
- 新兴的芳酶抑制剂对抗耐药性乳腺癌具有前途.
- 双抑制分子提供了一种减少药物耐药性的策略.
- 新型化合物的协同效应可能改善治疗结果.
结论:
- 新的芳香酶抑制剂对于促进乳腺癌治疗至关重要.
- 双重准策略是对抗抗性的有希望的方法.
- 对新型芳香酶抑制剂的持续研究对于有效的癌症治疗至关重要.
更多相关视频
相关概念视频
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...


